A. Ogden

发表

Pharmacological Characterization of the Competitive GLUK5 Receptor Antagonist Decahydroisoquinoline LY466195 in Vitro and in Vivo

David Bleakman, Kirk W. Johnson, Andrew Alt, 2006, Journal of Pharmacology and Experimental Therapeutics.

GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: in vitro profile and in vivo analgesic efficacy.

D. Clawson, P. Ornstein, S. Iyengar, 2013, Bioorganic & medicinal chemistry letters.

A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.

E. Meng, N. Peet, A. Ogden, 1990, Journal of medicinal chemistry.

Rapid down regulation of beta-adrenoceptors by co-administration of desipramine and fluoxetine.

J. Stegeman, A. Ogden, B. M. Baron, 1988, European journal of pharmacology.

Xanthines with C8 chiral substituents as potent and selective adenosine A1 antagonists.

N. Peet, A. Ogden, M. Racke, 1993, Journal of medicinal chemistry.

LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's Disease

E. Nisenbaum, K. Whalley, P. Skolnick, 2003, Journal of Pharmacology and Experimental Therapeutics.

Conformationally restrained, chiral (phenylisopropyl)amino-substituted pyrazolo[3,4-d]pyrimidines and purines with selectivity for adenosine A1 and A2 receptors.

N. Peet, S. Sunder, A. Ogden, 1992, Journal of medicinal chemistry.

ACET is a highly potent and specific kainate receptor antagonist: Characterisation and effects on hippocampal mossy fibre function

G. Collingridge, M. Mayer, D. Jane, 2009, Neuropharmacology.

5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents.

J. Kehne, J. Kane, A. Ogden, 1994, Journal of medicinal chemistry.

MDL 27,531 selectively reverses strychnine‐induced seizures in mice

J. Kehne, J. Kane, M. Palfreyman, 1992, British journal of pharmacology.

The enhancement and inhibition of in vivo binding of [3H]R015-1788 in mouse cerebral cortex by a series of 5-aryltriazoles

J. Kane, A. Ogden, B. Lippert, 1990 .

Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro

D. Bleakman, T. Large, A. Alt, 2004, Neuropharmacology.

Inflammatory Cytokines Enhance Muscarinic‐Mediated Arachidonic Acid Release Through p38 Mitogen‐Activated Protein Kinase in A2058 Cells

C. Felder, A. Ogden, R. Mark, 2000, Journal of neurochemistry.

LY 503430 , a novel AMPA receptor potentiator with functional , neuroprotective and neurotrophic effects in rodent models of Parkinson ’ s disease

E. Nisenbaum, K. Whalley, P. Skolnick, 2003 .

LY 503430 , a Novel-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional , Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson ’ s Disease

E. Nisenbaum, K. Whalley, P. Skolnick, 2003 .

Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist

G. Collingridge, D. Jane, Z. Bortolotto, 2004, Neuropharmacology.

Kainate receptors are involved in synaptic plasticity

G. Collingridge, Z. Bortolotto, P. Ornstein, 1999, Nature.

Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum

G. Gilmour, T. Belecky-Adams, Sally Loomis, 2015, Neuropharmacology.

In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders

Xia Li, J. Witkin, D. Bleakman, 2006, Psychopharmacology.

Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro

P. Ornstein, D. Bleakman, D. Zimmerman, 2001, Neuropharmacology.

Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro

D. Bleakman, D Bleakman, M Gates, 2001, Neuropharmacology.

Antagonists of GLUK5-containing kainate receptors prevent pilocarpine-induced limbic seizures

G. Collingridge, Z. Bortolotto, Y. Michotte, 2002, Nature Neuroscience.

GluK1 antagonists from 6-(carboxy)phenyl decahydroisoquinoline derivatives. SAR and evaluation of a prodrug strategy for oral efficacy in pain models.

P. Ornstein, S. Iyengar, M. del Prado, 2013, Bioorganic & medicinal chemistry letters.

Antiallodynic and Antihyperalgesic Effects of Selective Competitive GLUK5 (GluR5) Ionotropic Glutamate Receptor Antagonists in the Capsaicin and Carrageenan Models in Rats

P. Ornstein, S. Iyengar, D. Bleakman, 2006, Journal of Pharmacology and Experimental Therapeutics.

Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.

P. Ornstein, S. Iyengar, M. del Prado, 2005, Journal of medicinal chemistry.

Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.

Kirk W. Johnson, P. Ornstein, M. del Prado, 2002, Journal of medicinal chemistry.

LY339434, a GluR5 kainate receptor agonist

B. Ballyk, B. Small, D. Bleakman, 1998, Neuropharmacology.

Pharmacological characterization of a GluR6 kainate receptor in cultured hippocampal neurons.

P. Ornstein, D. Bleakman, A. Ogden, 1999, European journal of pharmacology.

TRP channels as emerging targets for pain therapeutics

M. Blanco, D. Bleakman, L. Broad, 2009, Expert opinion on therapeutic targets.

Pharmacological Modulation of GluK1 and GluK2 by NETO1, NETO2, and PSD95.

Kirk W. Johnson, Y. Qian, D. Bleakman, 2016, Assay and drug development technologies.

Kainate receptor agonists, antagonists and allosteric modulators.

D. Bleakman, A. Ogden, M. Gates, 2002, Current pharmaceutical design.